Allosteric Modulators of Dopamine Transporter as Therapeutic Agents for NeuroAIDS

多巴胺转运蛋白的变构调节剂作为神经艾滋病的治疗剂

基本信息

批准号：
10627748
负责人：
CORINNE ELIZABETH AUGELLI-SZAFRAN
金额：
$ 79.16万
依托单位：
SOUTHERN RESEARCH INSTITUTE
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-07-01 至 2025-04-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10627748
关键词：
Acceleration Acquired Immunodeficiency Syndrome Address Animal Model Attention Attenuated Behavioral Binding Binding Sites Biochemical Biological Assay Brain Cells Central Nervous System Chemosensitization Cocaine Cocaine Abuse Cognition Cognitive Cognitive deficits Complex Development Docking Dopamine Dose Drug Design Drug Kinetics Feedback Functional disorder Genetic Transcription Goals HIV HIV Seropositivity HIV-1 HIV-associated neurocognitive disorder Homeostasis Human Impaired cognition Impairment In Vitro Incidence Individual Infection Kinetics Lead Learning Ligands Mediating Memory Metabolic Modeling Moods Motivation Mus Neurocognitive Neurocognitive Deficit Neurologic Neuroprotective Agents Patients Penetration Performance Periodicity Permeability Persons Pharmaceutical Chemistry Pharmacology Study Pharmacotherapy Physiological Play Population Prevention Prevention strategy Property Proteins Public Health Publishing Quinazolines Research Research Personnel Rewards Role Series Severities Site Solubility Structure Structure-Activity Relationship Synapses Testing Therapeutic Therapeutic Agents Therapeutic Intervention Trans-Activators Transcription Coactivator Transgenic Mice Virus Diseases Virus Replication Work analog antiretroviral therapy attenuation behavioral pharmacology behavioral study blood-brain barrier crossing blood-brain barrier penetration candidate identification cocaine reward conditioned place preference design dopamine transporter dopaminergic neuron drug of abuse efficacy evaluation genetic regulatory protein improved in silico in vivo lead optimization lead series monoamine mutant neuroAIDS neurotoxicity neurotransmission novel novel strategies pharmacologic prevent reuptake small molecule transmission process uptake

项目摘要

PROJECT SUMMARY More than 37 million people are living with Human Immunodeficiency Virus (HIV) infection worldwide which continues to be a global public health problem. Despite the widespread use of antiretroviral therapy (ART), up to 70% of HIV-positive individuals suffer from cognitive and behavioral deficits collectively known as HIV-associated neurocognitive disorders (HAND), for which no therapeutic options are currently available. Converging lines of evidence indicate that the HIV-1 transactivator of transcription (Tat) protein plays a crucial role in causing neurotoxicity and cognitive impairment in HAND. HIV-1 Tat exerts its neurotoxicity through interaction with crucial proteins, such as the monoamine transporters in the central nervous system (CNS). The dysregulation of dopamine (DA) neurotransmission in HAND occurs through direct interaction of Tat protein with the DA transporter (DAT) which is essential for maintaining DA homeostasis and a target of cocaine. While most ARTs cannot efficiently cross the blood-brain barrier, Tat-induced increase in DA levels accelerates viral replication in the brain. Moreover, drugs of abuse, such as cocaine, exacerbate neurological impairments. Our published work has demonstrated that Tat-induced inhibition of DAT is mediated by binding of Tat to allosteric binding site(s) on DAT, not by interacting with the DA uptake site. This provides a basis for a novel approach to address the problem by developing compounds to attenuate Tat binding to DAT by an allosteric mechanism. Our recent studies with small molecule allosteric ligands of DAT reveal that these compounds are capable of attenuating Tat-mediated effects on DAT, thus providing a potential opportunity to develop therapeutic interventions for the treatment of HAND. The research effort proposed herein is to explore the hypothesis that disruption of Tat-DAT interactions with small molecule allosteric ligands of DAT, with minimal disruption of normal DA uptake, will have therapeutic potential for prevention of neurocognitive dysfunction in HAND. The primary goal of our research is to optimize lead compounds and perform proof-of-concept pharmacological studies in animal models. To this end, the specific aims to be pursed in the proposed effort are to: (1) design and synthesize novel allosteric ligands with improved physicochemical and pharmacokinetic properties using in silico property predictions and computational docking studies with DAT-Tat complex models, (2) characterize the allosteric interaction of the compounds with human DAT in vitro to identify optimized compounds with improved physicochemical properties that can be used to alleviate Tat-induced dysfunction of DAT, and (3) determine the efficacy of selected compounds in attenuating Tat-mediated cognitive deficits and rewarding effects of cocaine in inducible Tat transgenic mice in vivo. This collaborative effort involves investigators with complementary expertise in medicinal chemistry, drug design, and biochemical and behavioral studies with the long-term goal of developing drugs for the treatment of HAND in HIV-positive patients.

项目摘要全球有超过3700万人患有人类免疫缺陷病毒（HIV）感染仍然是全球公共卫生问题。尽管广泛使用抗逆转录病毒疗法（ART），但 70％的HIV阳性个体遭受认知和行为缺陷，共同被称为HIV相关神经认知障碍（手），目前尚无治疗选择。汇合线证据表明，HIV-1转录（TAT）蛋白的反式激活剂在引起手头的神经毒性和认知障碍。 HIV-1 TAT通过与关键的相互作用发挥其神经毒性蛋白质，例如中枢神经系统（CNS）中的单胺转运蛋白。失调多巴胺（DA）神经传递是通过TAT蛋白与DA的直接相互作用而发生的转运蛋白（DAT），这对于维持DA稳态和可卡因目标至关重要。而大多数艺术无法有效地越过血脑屏障，TAT诱导的DA水平的增加会加速病毒复制大脑。此外，滥用药物，例如可卡因，加剧神经系统障碍。我们发表的作品已经证明，TAT诱导的DAT抑制是通过TAT与变构结合位点结合在上介导的 DAT，不是通过与DA吸收站点进行交互。这为解决这个方法提供了一种基础通过开发化合物通过变构机制来减弱TAT与DAT结合的问题。我们最近 DAT的小分子变构配体的研究表明，这些化合物能够减弱 TAT介导的对DAT的影响，从而为开发治疗干预措施提供了潜在的机会手的治疗。本文提出的研究工作是探讨tat-dat中断的假设与小分子变构配体的相互作用，而正常DA摄取的破坏最小，将具有手工预防神经认知功能障碍的治疗潜力。我们研究的主要目标是优化铅化合物并在动物模型中进行概念验证药理研究。对此最后，在拟议的努力中要追求的具体目标是：（1）设计和综合新型变构。在硅特性预测中，配体具有改进的物理化学和药代动力学特性使用DAT-TAT复合模型的计算对接研究，（2）表征在体外具有人类DAT的化合物，以鉴定具有改进理化特性的优化化合物可以用来减轻TAT诱导的DAT功能障碍，（3）确定所选的功效衰减Tat介导的认知缺陷和可卡因在诱导型TAT中的奖励作用的化合物体内转基因小鼠。这项合作努力涉及具有互补专业知识的研究人员化学，药物设计以及生化和行为研究的长期目标是开发用于 HIV阳性患者的手治疗。